

Hongmei Gao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3577680/publications.pdf>

Version: 2024-02-01

20
papers

1,259
citations

623574

14
h-index

677027

22
g-index

22
all docs

22
docs citations

22
times ranked

2331
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. <i>Journal of Immunological Methods</i> , 2014, 409, 131-146.	0.6	435
2	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005520.	2.1	150
3	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. <i>Journal of Virology</i> , 2015, 89, 2659-2671.	1.5	123
4	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016, 12, e1005742.	2.1	81
5	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. <i>Journal of Virology</i> , 2014, 88, 12623-12643.	1.5	75
6	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	2.1	56
7	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. <i>PLoS ONE</i> , 2017, 12, e0180720.	1.1	55
8	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	5.6	53
9	Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. <i>Journal of Immunology</i> , 2016, 197, 4603-4612.	0.4	44
10	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007431.	2.1	36
11	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. <i>Science Immunology</i> , 2021, 6, .	5.6	34
12	Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
13	Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B ϵ -infected former plasma donors from China naïve to antiretroviral therapy. <i>Journal of General Virology</i> , 2012, 93, 2267-2278.	1.3	21
14	Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 753444.	1.8	13
15	The pigtail macaque (<i>Macaca nemestrina</i>) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease. <i>PLoS Pathogens</i> , 2021, 17, e1010162.	2.1	11
16	Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. <i>Journal of Immunological Methods</i> , 2020, 479, 112736.	0.6	9
17	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. <i>Retrovirology</i> , 2021, 18, 35.	0.9	7
18	Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy. <i>Scientific Reports</i> , 2017, 7, 46308.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. <i>Vaccine</i> , 2021, 39, 3879-3891.	1.7	3
20	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. <i>Cell Reports Medicine</i> , 2022, 3, 100635.	3.3	3